Abstract
The purpose of this study was to determine whether oral pentoxifylline would improve retinal microvascular hemodynamics and blood rheology in patients with diabetes. Patients were enrolled in a double-masked, placebo-controlled trial of pentoxifylline at 2000 mg/d. Retinal capillary blood velocity and leukocyte density, filterability, viscosity, and fibrinogen content were measured by the blue-field entoptic phenomenon simulation, filtration, rotational viscosimetry, and heat precipitation techniques, respectively, before, during, and after drug therapy. Treatment with pentoxifylline resulted in a 23.2%, 26.8%, and 37.8% increase in capillary blood flow velocity at 1, 2, and 3 months of therapy, respectively, with a return to pretreatment baseline levels 1 month after cessation of therapy. There were no apparent effects on the remaining variables during treatment. Pentoxifylline increases retinal capillary blood flow velocity in patients with diabetes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
